Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | U266 is a human B-lymphocyte multiple myeloma (plasma cell myeloma) cell line established by K. Nilsson in 1968. The cell line was isolated from the peripheral blood of a 53-year-old Caucasian male patient suffering from refractory, end-stage, IgE-secreting myeloma. U266 cells range in shape from round to polygonal and primarily grow in suspension (forming single cells or clusters), with only a small subpopulation exhibiting loosely adherent growth characteristics. It is a globally recognized, classic cornerstone model for the in vitro study of B-lymphocyte malignancies. Notable for their natural production of human interleukin-6 (IL-6) and monoclonal IgE lambda (λ) antibodies, U266 cells serve as an indispensable tool in multiple myeloma research, cytokine signaling studies, and as fusion partners for the generation of human hybridomas. |
| Tissue | Blood / Lymphoid; derived from Peripheral Blood |
| Cell Type | B Lymphocyte / Plasma cell |
| Disease | Multiple Myeloma / Plasma Cell Leukemia |
| Morphology | Lymphoblast-like; round to polygonal cells in suspension with occasional loose adherence |
| Gender | Male |
| Age | 53 years |
| Product Format | Frozen |
| Growth Mode | Suspension (with some cells growing loosely attached to the vessel floor) |
| Biosafety Level | 1 (Biosafety classification matches standard laboratory parameters for non-infectious human blood-derived tumor lines) |
| Applications | 1. Conduct in vitro modeling studies directly addressing the pathogenesis, therapeutic targets, and signaling pathways of high-risk plasmacytomas in multiple myeloma. 2. Investigate the autocrine IL-6/gp130 signaling loop and downstream JAK/STAT or BCL2 cell survival networks. 3. Serve as a fusion partner for generating human-human hybridoma cells that produce monoclonal antibodies. 4. Perform preclinical screening for next-generation immunotherapies, proteasome inhibitors (e.g., bortezomib), and candidate drugs targeting myeloma. 5. Establish systemic or localized multiple myeloma xenograft models in highly immunodeficient animal hosts (e.g., NSG mice). |
| Shipped In | Dry ice |
| Storage Temperature | −196°C (Liquid nitrogen vapor phase only) |
| Characteristics | |
| Tumorigenic | Yes, highly tumorigenic; forms progressive multiple myeloma tumors in immunocompromised mice. |
| Secretory & Synthesis Profile | 1. Immunoglobulin: Naturally synthesizes and secretes intact IgE lambda (λ) monoclonal antibodies. 2. Cytokine autocrine loop: Produces human IL-6, thereby enabling IL-6-independent autonomous proliferation in culture. |
| Karyotype | Human complex hypodiploid karyotype with approximately 6.5% polyploidy. Modal chromosome distribution center is 44 (ranges 40-46, XY). |
| Immunophenotype | Strongly positive for CD138 (Syndecan-1) and cIg-lambda (λ); weakly positive for HLA-DR; completely negative for CD3, CD10, CD13, CD19, CD20, CD34, CD37, CD38, CD80, and cIg-kappa (κ). |
| Growth Kinetics | Relatively slow suspension expansion; typical population doubling time is approximately 55 hours. |
| Mycoplasma Test | Negative |
| Culture Conditions and Handling | |
| Subculturing | 1. As these cells grow primarily in suspension, enzymatic treatment (such as trypsinization) is completely unnecessary. 2. Gently shake or swirl the culture vessel to create a uniform cell suspension. If a small number of cells are loosely adherent, they can be gently dislodged or removed by rinsing with a bent-tip Pasteur pipette; trypsin is not required. 3. Transfer the medium containing the cell suspension into a sterile conical centrifuge tube. 4. Centrifuge at approximately 125 X g (or 1000 rpm) for 5 to 7 minutes to pellet the cells. 5. Carefully aspirate and discard the supernatant, ensuring the cell pellet remains undisturbed. 6. Gently resuspend the cell pellet in fresh, pre-warmed complete growth medium. 7. Transfer to a new culture vessel. Critical density range: Seeding at too low a density can induce apoptosis. Strictly maintain the working density between 0.2 X 10^6 and 1.0 X 10^6 cells/mL. Do not allow the cell density to exceed 1.5 X 10^6 cells/mL. |
| Medium Renewal | Every 2 to 3 days |
| Subcultivation Ratio | Split saturated suspension cultures at a ratio of 1:2 to 1:4. |
| Culture Conditions | Atmosphere: Air, 95%; CO2, 5%; Temperature: 37°C |
| Cryopreservation | 90% Complete culture medium + 10% DMSO (or 70% Basal medium + 20% FBS + 10% DMSO) |
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-RR0567M | GFP/Luc Reporter Cell Line - U266 | Inquiry |
| CSC-RR00854 | GFP Reporter Cell Line - U266 | Inquiry |
| CSC-RR00855 | Luciferase Reporter Cell Line - U266 | Inquiry |
| CSC-RO01663 | OVAL Stable Cell Line - U266 | Inquiry |
| CSC-RO01916 | GFP/OVAL Stable Cell Line - U266 | Inquiry |
| CSC-RO02169 | Luc/OVAL Stable Cell Line - U266 | Inquiry |
| CSC-RO02422 | GFP/Luc/OVAL Stable Cell Line - U266 | Inquiry |
The above is only part of a part of cell line products. If you don't find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
Copyright © 2026 Creative Biogene. All rights reserved.